The startup operates a multi-omics platform that integrates biological data and machine learning to analyze molecular processes related to autism spectrum disorder (ASD). This technology enables healthcare professionals to identify biomarker signatures, enhancing treatment decisions and facilitating the discovery of new drug targets for ASD care.
Funding
$1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current diagnostic methods for Autism Spectrum Disorder (ASD) rely on subjective behavioral assessments, which can lead to late or inaccurate diagnoses. This delay limits access to timely interventions and personalized treatment plans for individuals with ASD.
Solution
Point6 Bio is developing a multi-omics platform that integrates biological data with machine learning to provide objective insights into the molecular processes underlying ASD. By analyzing blood and breath samples, the platform identifies unique biomarker signatures that reflect the biological mechanisms of ASD. This approach enables healthcare professionals to make earlier and more accurate diagnoses, facilitating personalized treatment decisions and the discovery of new drug targets. The platform aims to shift the paradigm of ASD care by providing faster, scalable, and objective diagnostics rooted in biological data.
Target Audience
The primary target audience includes healthcare professionals, such as physicians, therapists, and diagnosticians, involved in the diagnosis and treatment of Autism Spectrum Disorder (ASD).
Features
- Multi-omics data integration for comprehensive molecular insights
- Machine learning algorithms to identify biomarker signatures
- Analysis of minimally invasive blood and breath samples
- Objective diagnostic tools for faster and more accurate ASD detection
- Identification of potential targets for personalized treatments